next message in archive
no next message in thread
previous message in archive
Index of Subjects
ax010 Stock Buyer's Alert! Stock Of The Month: Hard to Treat Diseases, Inc. (OTC: HTDS) Current Price: .05 Target Price: .35 in 10 days Major Medical Breakthrough: Live Cancer Trials Begin on HTDS Patented Product, Stock Set To Explode! HTDS holds the U.S. and international marketing rights, except South Korea, to a safe, non-toxic, non-addictive cancer combatant called Tubercin (US Patent 6,274,356). All testing is being performed under strict FDA guidelines for Tubercin which increases the strength of the immune system and is capable of destroying cancer cells. Tubercin has already passed and completed the toxicity testing phase as required by the FDA, enabling HTDS to make rapid progress with cancer trials on live Melanoma, Lung, and Breast Cancer cells. All testing of Tubercin is being performed by a well-known, highly regarded U.S. medical group insuring the adherence to proper FDA protocol. HTDS has reported that each phase of the required FDA process has been remarkably smooth and produced the first positive breakthrough in the U.S. as part of an independent medical study. The abstract summary clearly states in the patent description for Tubercin that it "is highly effective in treating various cancer patients without incurring any adverse side effects." We look for HTDS to be a superior performer for any investment portfolio based on the huge multi-million dollar worldwide market for a patented medical breakthrough product of this caliber. Stock Buyer's Alert (SBA) cautions that small and micro-cap stocks are high-risk investments and that some or all investment dollars can be lost. We suggest you consult a professional investment advisor before purchasing any stock. All opinions expressed on the featured company are the opinions of SBA. SBA recommends you use the information found here as an initial starting point for conducting your own research and your own due diligence on the featured company in order to determine your own personal opinion of the company before investing. SBA is not an Investment Advisor, Financial Planning Service or a Stock Brokerage Firm and in accordance with such is not offering investment advice or promoting any investment strategies. SBA is not offering securities for sale or solicitation of any offer to buy or sell securities. SBA has received ten thousand dollars from a third party for the dissemination of this company profile. Since we have received compensation there is an inherent conflict of interest in our statements and opinions. Readers of this publication are cautioned not to place undue reliance on forward-looking statements, which are based on certain assumptions and expectations involving various risks and uncertainties, that could cause results to differ materially from those set forth in the forward- looking statements.
next message in archive
no next message in thread
previous message in archive
Index of Subjects